DexCom, Inc. (DXCM): Price and Financial Metrics


DexCom, Inc. (DXCM): $424.85

2.75 (+0.65%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

DXCM POWR Grades


  • DXCM scores best on the Quality dimension, with a Quality rank ahead of 88.31% of US stocks.
  • DXCM's strongest trending metric is Quality; it's been moving up over the last 163 days.
  • DXCM ranks lowest in Momentum; there it ranks in the 10th percentile.

DXCM Stock Summary

  • With a market capitalization of $42,126,192,858, Dexcom Inc has a greater market value than 93.83% of US stocks.
  • With a one year PEG ratio of 430.8, Dexcom Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 94.07% of US stocks.
  • Price to trailing twelve month operating cash flow for DXCM is currently 82.81, higher than 95.49% of US stocks with positive operating cash flow.
  • If you're looking for stocks that are quantitatively similar to Dexcom Inc, a group of peers worth examining would be EBAY, MCHP, FTNT, CDNS, and RMD.
  • Visit DXCM's SEC page to see the company's official filings. To visit the company's web site, go to www.dexcom.com.

DXCM Valuation Summary

  • In comparison to the median Healthcare stock, DXCM's price/sales ratio is 107.93% higher, now standing at 23.6.
  • DXCM's price/sales ratio has moved NA NA over the prior 199 months.
  • Over the past 199 months, DXCM's EV/EBIT ratio has gone up 167.3.

Below are key valuation metrics over time for DXCM.

Stock Date P/S P/B P/E EV/EBIT
DXCM 2021-08-31 23.6 25.6 96.5 146.9
DXCM 2021-08-30 23.3 25.3 95.1 144.7
DXCM 2021-08-27 23.2 25.2 94.9 144.5
DXCM 2021-08-26 23.1 25.0 94.3 143.5
DXCM 2021-08-25 23.1 25.1 94.4 143.6
DXCM 2021-08-24 23.0 25.0 94.0 143.0

DXCM Growth Metrics

    Its 2 year net cashflow from operations growth rate is now at 266.99%.
  • Its 4 year net cashflow from operations growth rate is now at 570.93%.
  • The 3 year net income to common stockholders growth rate now stands at -103.13%.
DXCM's revenue has moved up $1,873,800,000 over the prior 67 months.

The table below shows DXCM's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 2,319.2 508.7 529.3
2021-06-30 2,169.9 409 530.6
2021-03-31 2,026.6 501.5 514
2020-12-31 1,926.7 475.6 493.6
2020-09-30 1,820.6 447.3 231.1
2020-06-30 1,716 394.2 204.7

DXCM's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • DXCM has a Quality Grade of B, ranking ahead of 87.89% of graded US stocks.
  • DXCM's asset turnover comes in at 0.517 -- ranking 89th of 186 Medical Equipment stocks.
  • VRAY, ZYXI, and SRTS are the stocks whose asset turnover ratios are most correlated with DXCM.

The table below shows DXCM's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.517 0.693 0.081
2021-06-30 0.510 0.692 0.077
2021-03-31 0.506 0.675 0.070
2020-12-31 0.547 0.664 0.077
2020-09-30 0.597 0.654 0.089
2020-06-30 0.651 0.639 0.090

DXCM Price Target

For more insight on analysts targets of DXCM, see our DXCM price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $530.60 Average Broker Recommendation 1.36 (Strong Buy)

DXCM Stock Price Chart Interactive Chart >

Price chart for DXCM

DXCM Price/Volume Stats

Current price $424.85 52-week high $659.45
Prev. close $422.10 52-week low $318.45
Day low $402.59 Volume 761,140
Day high $425.09 Avg. volume 954,805
50-day MA $541.69 Dividend yield N/A
200-day MA $489.93 Market Cap 41.18B

DexCom, Inc. (DXCM) Company Bio


DexCom focuses on the design, development, and commercialization of continuous glucose monitoring systems for patients with diabetes. The company was founded in 1999 and is based in San Diego, California.


DXCM Latest News Stream


Event/Time News Detail
Loading, please wait...

DXCM Latest Social Stream


Loading social stream, please wait...

View Full DXCM Social Stream

Latest DXCM News From Around the Web

Below are the latest news stories about Dexcom Inc that investors may wish to consider to help them evaluate DXCM as an investment opportunity.

Docusign, Zoom, Moderna become the worst performing Nasdaq stocks

Yahoo Finance's Julie Hyman and Brian Sozzi discuss the worst performers in the Nasdaq 100 and upcoming Big Tech earnings.

Yahoo | January 20, 2022

Tiidal Gaming's Technology Division Enters Partnership with EveryMatrix Group

-The integration partnership will enable Tiidal Gaming to distribute its B2B betting solutions to EveryMatrix's network of sportsbooks- Toronto, Ontario--(Newsfile Corp. - January 20, 2022) - Tiidal Gaming Group Corp. (CSE: TIDL) ("Tiidal Gaming" or the "Company"), a leading esports and gaming platform company, is pleased to announce that the Company's wholly-owned subsidiary, Sportsflare ("Sportsflare") has entered a partnership with EveryMatrix Group ("EveryMatrix") to integrate Sportsflare's

Yahoo | January 20, 2022

DexCom raised to Overweight at Wells Fargo on upcoming catalyst and sales potential

Following a three-day selloff, DexCom (DXCM +2.9%) shares are trading higher after Wells Fargo upgraded the maker of continuous glucose monitoring (CGM) systems to Overweight from Equal Weight. The price target set to $575 per share implies a premium of ~33.8% to the last close. The upcoming launch of the...

Seeking Alpha | January 19, 2022

Dexcom (DXCM) Received its Third Buy in a Row

After Guggenheim and Piper Sandler gave Dexcom (NASDAQ: DXCM) a Buy rating last month, the company received another Buy, this time from Raymond James. Analyst Jayson Bedford maintained a Buy rating on Dexcom today and set a price target of $538.00. The company's shares closed last Tuesday at $429.87. According to TipRanks.com, Bedford is a 5-star analyst with an average return of 14.4% and a 72.0% success rate. Bedford covers the Healthcare sector, focusing on stocks such as Edwards Lifesciences, Tandem Diabetes Care, and Baxter International. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Dexcom with a $628.91 average price target, a 43.

Christine Brown on TipRanks | January 19, 2022

10 Jim Cramer Stocks to Buy in Q1 2022

In this article, we discuss the 10 Jim Cramer stocks to buy in Q1 2022. If you want to skip our detailed analysis of these stocks, go directly to the 5 Jim Cramer Stocks to Buy in Q1 2022. Investors have been scrambling to identify the “real value” of stocks as reports suggest that as […]

Yahoo | January 19, 2022

Read More 'DXCM' Stories Here

DXCM Price Returns

1-mo N/A
3-mo -24.89%
6-mo -7.63%
1-year 14.79%
3-year 192.98%
5-year 425.15%
YTD -20.88%
2021 45.23%
2020 69.02%
2019 82.59%
2018 108.75%
2017 -3.87%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8759 seconds.